文献速递中毒与环境急症消化、代谢与肾脏急症

停止尿液碱化后水杨酸盐毒性反弹的发生率

Incidence of rebound salicylate toxicity following cessation of urine alkalinization.
PubMed 文献 · Clin Toxicol (Phila) · 2023-07-10
一句话结论水杨酸盐中毒患者停止静脉碳酸氢钠碱化尿液后,血清水杨酸盐浓度反弹发生率低(2.1%),即使反弹至超治疗浓度,症状常缺如或轻微;作者认为除非症状复发,常规复查血清水杨酸盐浓度可能不必要。

这项单中心回顾性研究分析了当地中毒中心五年内报告的377例以乙酰水杨酸为主要摄入物的病例,排除主要摄入物未列出或停止静脉碳酸氢钠输注后无血清水杨酸盐浓度记录者。主要终点为停止静脉碳酸氢钠输注后血清水杨酸盐浓度反弹至大于300 mg/L(2.17 mmol/L)的发生率。结果显示8例(2.1%)出现反弹,均为急性摄入;其中5例反弹浓度大于300 mg/L(2.17 mmol/L),仅1例报告症状复发(耳鸣)。停止碱化前最后或最后两次血清水杨酸盐浓度低于300 mg/L(2.17 mmol/L)者分别为3例和2例。作者认为反弹发生率低,症状常缺如或轻微,除非症状复发,常规复查血清水杨酸盐浓度可能不必要。

要点

  • 377例乙酰水杨酸中毒患者中,停止静脉碳酸氢钠后血清水杨酸盐反弹发生率为2.1%(8/377),均为急性摄入。
  • 8例反弹中5例血清水杨酸盐浓度大于300 mg/L(2.17 mmol/L),仅1例报告症状复发(耳鸣)。
  • 停止碱化前最后或最后两次血清水杨酸盐浓度低于300 mg/L(2.17 mmol/L)者分别为3例和2例。
  • 作者认为,除非症状复发,停止尿液碱化后常规复查血清水杨酸盐浓度可能不必要。

适用人群与场景

  • 以乙酰水杨酸为主要摄入物、报告至当地中毒中心的病例。
  • 排除主要摄入物未列为乙酰水杨酸者,以及停止静脉碳酸氢钠输注后无血清水杨酸盐浓度记录者。

诊断标准与关键阈值

  • 停止尿液碱化的策略之一:等待连续两次血清水杨酸盐浓度低于300 mg/L(2.17 mmol/L)且呈下降趋势。
  • 反弹定义:停止静脉碳酸氢钠输注后血清水杨酸盐浓度升高至大于300 mg/L(2.17 mmol/L)。

红旗征与不能漏的情况

  • 停止尿液碱化后血清水杨酸盐浓度可因组织再分布或胃肠道吸收延迟而反弹。
  • 反弹至超治疗浓度时症状常缺如或轻微,但本研究中1例报告症状复发(耳鸣)。

研究设计与关键结果

  • 单中心回顾性研究,纳入当地中毒中心五年内报告的377例以乙酰水杨酸为主要摄入物的病例。
  • 8例(2.1%)在停止静脉碳酸氢钠输注后出现血清水杨酸盐浓度升高(反弹),均为急性摄入。
  • 8例反弹中5例血清水杨酸盐浓度大于300 mg/L(2.17 mmol/L),其中仅1例报告症状复发(耳鸣)。
  • 停止尿液碱化前,最后或最后两次血清水杨酸盐浓度低于300 mg/L(2.17 mmol/L)者分别为3例和2例。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,水杨酸盐中毒患者停止尿液碱化后血清水杨酸盐浓度反弹发生率低,即使反弹至超治疗浓度,症状常缺如或轻微。
  • 作者认为,除非症状复发,停止尿液碱化后常规复查血清水杨酸盐浓度可能不必要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Management of patients with salicylate toxicity frequently requires urine alkalinization to enhance excretion of salicylate. One strategy for determining when to stop urine alkalinization is to wait for two consecutive serum salicylate concentrations to be less than 300 mg/L (2.17 mmol/L) and declining. When alkalinization of the urine ceases, a rebound in serum salicylate concentration can occur from tissue redistribution or delayed gastrointestinal absorption. Whether this can lead to rebound toxicity is not well understood.

METHODS: This was a single-center, retrospective review of cases with a primary ingestion of acetylsalicylic acid reported to the local poison center over a five-year period. Cases were excluded if the product was not listed as the primary ingestion or if there was no serum salicylate concentration documented after discontinuation of intravenous sodium bicarbonate infusion. The primary outcome was the incidence of serum salicylate rebound to a concentration greater than 300 mg/L (2.17 mmol/L) after discontinuation of intravenous sodium bicarbonate infusion.

RESULTS: A total of 377 cases were included. Of these, eight (2.1%) had a serum salicylate concentration increase (rebound) after stopping the sodium bicarbonate infusion. All these cases were acute ingestions. Five of the eight cases had rebound serum salicylate concentrations that were greater than 300 mg/L (2.17 mmol/L). Of these five patients, only one reported recurrent symptoms (tinnitus). Prior to stopping urinary alkalinization, the last or the last two serum salicylate concentrations were less than 300 mg/L (2.17 mmol/L) in three and two cases, respectively.

CONCLUSIONS: In patients with salicylate toxicity, the incidence of rebound in serum salicylate concentration after cessation of urine alkalinization, is low. Even if serum salicylate rebounds to supratherapeutic concentrations, symptoms are often absent or mild. Routine repeat serum salicylate concentrations after urine alkalinization is stopped may be unnecessary unless symptoms recrudesce.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. O'Keefe M, Stanton M, Feldman R, et al. Incidence of rebound salicylate toxicity following cessation of urine alkalinization. Clin Toxicol (Phila). 2023. PMID: 37427892. doi:10.1080/15563650.2023.2227998

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。